MRI Scanning for Pancreatic Cancer Detection
(DWI-PDAC Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
Diffusion-weighted magnetic resonance imaging (DWI/MRI) has been described in recent literature as a highly sensitive and specific modality for the detection of peritoneal metastases (PM). It has been demonstrated to be superior to computed tomography (CT) for patients with known peritoneal disease from colorectal and gynaecological malignancies. However, the literature is scarce on the role of DWI/MRI in patients with pancreatic ductal-adenocarcinoma (PDAC). The aim of this study is to prospectively assess the added value of whole-body DWI/MRI (WB-DWI/MRI) to CT for detection of PM in the preoperative staging of patients with high-risk PDAC and evaluate how it correlates with intraoperative findings.
Who Is on the Research Team?
Alexandre Brind'Amour, MD
Principal Investigator
Laval University
Are You a Good Fit for This Trial?
This trial is for individuals with confirmed pancreatic ductal adenocarcinoma that can potentially be removed by surgery. They should have a tumor size of at least 3 cm and elevated CA 19-9 levels without distant metastases. Participants must be physically fit enough for pancreatic resection (ECOG performance status of 0 or 1).Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging Assessment
Participants undergo whole-body DWI/MRI within 4 weeks of planned surgery to assess for peritoneal metastases
Surgical Evaluation
Participants with no evidence of PM on WB-DWI/MRI undergo pancreatic resection; those with suspicion of PM undergo diagnostic laparoscopy first
Follow-up
Participants are monitored for early distant recurrence and unexpected aborted surgery due to peritoneal metastases discovery
What Are the Treatments Tested in This Trial?
Interventions
- Whole-body diffusion-weighted magnetic resonance imaging
Find a Clinic Near You
Who Is Running the Clinical Trial?
Laval University
Lead Sponsor